生脉注射液对充血性心力衰竭患者TRAIL死亡受体的影响

目的探讨充血性心力衰竭(congestiveheartfailure,CHF)患者可溶性肿瘤坏死因子相关的凋亡诱导配体(tumornecrosisfactorrelatedapoptosisinducingligand,TRAIL)死亡受体(Deathreceptor,DR)sDR4和sDR5的水平及生脉注射液对其影响。方法64例CHF患者随机分为生脉注射液治疗组(生脉治疗组)及常规治疗组;并设健康对照组。采用夹心ELISA法检测患者治疗前后血浆中sDR4和sDR5水平。结果CHF患者sDR4和sDR5水平均明显高于健康人,差异有显著性(P<0.01);且随着心功能损害程度的加重而升高。生脉治疗组和常规治疗组治疗后血浆中sDR4、sDR5水平降低,生脉治疗组优于常规治疗组。结论TRAIL死亡受体DR4和DR5水平与心功能损害程度关系密切,可能在CHF患者心肌细胞凋亡的发生、发展进程中起着重要作用。生脉注射液可降低CHF患者的sDR4、sDR5水平,在减缓CHF进程、改善心功能中可能具有重要作用。

英文摘要:

Objective To explore the levels of DR4 and DR5, the death receptor of soluble tumor necrosis factor-related apoptosis inducing ligand (TRAIL) in the patients with congestive heart failure (CHF) and the effect of Shengmai Injection (SI) on them. Methods Sixty-four CHF patients were randomized into two groups, the SI group treated by SI and the control group treated with conventional treatment. Another 30 healthy persons were enrolled as the healthy control group. The serum levels of sDR4 and sDR5 were determined by sandwich ELISA before and after treatment. Results [WT5BZ]The serum levels of sDR4 and sDR5 were obviously higher in CHF patients than in the healthy control subjects (P<0.01), showing a rising trend with the aggravation of the degree of cardiac function impairment. Levels of sDR4 and sDR5 were lowered in the two treated groups after treatment, with better effects gotten in the SI group. Conclusion Close relationship presents between cardiac function status and levels of DR4 and DR5 in patients with CHF. DR4 and DR5 might play an important role in the occurrence and progression of myocardial cell apoptosis in patients with CHF, and SI may acts vitally to slow down the progress of CHF and improve patients’ heart function by decreasing the levels of sDR4 and sDR5.

关闭